[go: up one dir, main page]

WO2004010943A3 - Benzanilides substitues utilises comme modulateurs du recepteur ccr5 - Google Patents

Benzanilides substitues utilises comme modulateurs du recepteur ccr5 Download PDF

Info

Publication number
WO2004010943A3
WO2004010943A3 PCT/US2003/023524 US0323524W WO2004010943A3 WO 2004010943 A3 WO2004010943 A3 WO 2004010943A3 US 0323524 W US0323524 W US 0323524W WO 2004010943 A3 WO2004010943 A3 WO 2004010943A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccr5
receptor
modulators
treatment
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/023524
Other languages
English (en)
Other versions
WO2004010943A2 (fr
Inventor
William E Bondinell
Michael J Neeb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to AU2003256923A priority Critical patent/AU2003256923A1/en
Publication of WO2004010943A2 publication Critical patent/WO2004010943A2/fr
Publication of WO2004010943A3 publication Critical patent/WO2004010943A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne des benzanilides substitués qui sont des modulateurs, des agonistes ou des antagonistes, du récepteur CCR5. Par ailleurs, la présente invention concerne également le traitement et la prévention d'états pathologiques induits par CCR5, y compris, sans en exclure d'autres, les troubles asthmatiques et atopiques (tels que les dermatites et les allergies atopiques), la polyarthrite rhumatoïde, la sarcoïdose et d'autres maladies fibrotiques, l'athérosclérose, le psoriasis, les maladies auto-immunes, telles que la sclérose en plaques, et l'affection abdominale inflammatoire, chez des mammifères, ces traitements consistant à utiliser des benzanilides substitués qui sont des antagonistes du récepteur CCR5. De plus, du fait que des lymphocytes T CD8+ ont été impliqués dans la BPCO (bronchopneumopathie chronique obstructive), CCR5 peut avoir un rôle dans leur recrutement et, ainsi, les antagonistes de CCR5 pourraient fournir un effet thérapeutique potentiel dans le traitement de la BPCO. Par ailleurs, du fait que CCR5 est un co-récepteur pour l'entrée du VIH dans les cellules, les modulateurs des récepteurs sélectifs peuvent être utiles dans le traitement d'une infection par le VIH.
PCT/US2003/023524 2002-07-31 2003-07-28 Benzanilides substitues utilises comme modulateurs du recepteur ccr5 Ceased WO2004010943A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003256923A AU2003256923A1 (en) 2002-07-31 2003-07-28 Substituted benzanilides as modulators of the ccr5 receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40025702P 2002-07-31 2002-07-31
US60/400,257 2002-07-31

Publications (2)

Publication Number Publication Date
WO2004010943A2 WO2004010943A2 (fr) 2004-02-05
WO2004010943A3 true WO2004010943A3 (fr) 2004-09-16

Family

ID=31188674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023524 Ceased WO2004010943A2 (fr) 2002-07-31 2003-07-28 Benzanilides substitues utilises comme modulateurs du recepteur ccr5

Country Status (2)

Country Link
AU (1) AU2003256923A1 (fr)
WO (1) WO2004010943A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249085B2 (en) 2011-09-16 2016-02-02 Fovea Pharmaceuticals Aniline derivatives, their preparation and their therapeutic application

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
JP2008501031A (ja) 2004-05-28 2008-01-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド ムスカリン受容体のモジュレーター
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008510728A (ja) 2004-08-19 2008-04-10 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
US7863449B2 (en) 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2007025240A1 (fr) * 2005-08-25 2007-03-01 Bright Entertainment Limited Fourniture d'experience interactive avec un contenu audiovisuel
EP1988892A2 (fr) 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulateurs des récepteurs muscariniques
CN101500565A (zh) 2006-06-29 2009-08-05 弗特克斯药品有限公司 毒蕈碱性受体的调节剂
ES2652664T3 (es) * 2011-12-01 2018-02-05 Chemocentryx, Inc. Anilinas sustituidas como antagonistas de CCR(4)
EA026368B1 (ru) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
AU2013307337B2 (en) 2012-08-28 2018-07-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
US9650337B2 (en) 2013-02-14 2017-05-16 Galderma Research & Development Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate
CN105189453B (zh) 2013-02-28 2018-04-10 爱尔兰詹森科学公司 氨磺酰基‑芳基酰胺及其作为用于乙型肝炎治疗的药物的用途
WO2014161888A1 (fr) 2013-04-03 2014-10-09 Janssen R&D Ireland Dérivés de n-phénylcarboxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CA2935719C (fr) 2013-07-25 2021-11-02 Janssen Sciences Ireland Uc Derives de pyrrolamide a substitution glyoxamide et leur utilisation en tant que medicaments pour le traitement de l'hepatite b
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
JP6495929B2 (ja) 2014-02-06 2019-04-03 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイルピロールアミド誘導体およびｂ型肝炎の治療のための医薬としてのその使用
AU2016232801A1 (en) 2015-03-19 2017-10-12 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
NZ773164A (en) 2018-08-29 2025-07-25 Chemocentryx Inc Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
CA3127152A1 (fr) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Derives d'amide utiles dans le traitement d'une infection par le virus de l'hepatite b ou de maladies induites par le virus de l'hepatite b
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026328A1 (fr) * 1994-03-26 1995-10-05 Smithkline Beecham Plc Derives biphenyles en tant qu'antagonistes du 5ht1d

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026328A1 (fr) * 1994-03-26 1995-10-05 Smithkline Beecham Plc Derives biphenyles en tant qu'antagonistes du 5ht1d

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249085B2 (en) 2011-09-16 2016-02-02 Fovea Pharmaceuticals Aniline derivatives, their preparation and their therapeutic application
US9624159B2 (en) 2011-09-16 2017-04-18 Sanofi Aniline derivatives, their preparation and their therapeutic application

Also Published As

Publication number Publication date
WO2004010943A2 (fr) 2004-02-05
AU2003256923A8 (en) 2004-02-16
AU2003256923A1 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
WO2004011427A3 (fr) Benzanilides substitues utilises en tant que modulateurs du recepteur ccr5
WO2004010943A3 (fr) Benzanilides substitues utilises comme modulateurs du recepteur ccr5
IL133730A0 (en) Compounds and methods substituted benzanilides as ccr5 ligands
WO2004010942A3 (fr) Composes heterocycliques substitues utilises comme modulateurs du recepteur ccr5
EP1140072A4 (fr) Composes et procedes
AR013669A1 (es) Compuestos y metodos
UA103634C2 (en) Azaindazole compounds as ccr1 receptor antagonists
DK1718649T3 (da) Imidazo[1,2-c]pyrimidinyleddikesyrederivater
AU3521400A (en) Compounds and methods
MX2011011338A (es) Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
JOP20170136B1 (ar) ستخدام مركبات إندازول مستبدل في الموقع 2 للمعالجة والوقاية من اضطرابات المناعة الذاتية
TN2012000061A1 (en) (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
MX2010001307A (es) Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
WO2008100618A3 (fr) Modulateurs de cathepsine s à la tétrahydro-pyrazolo-pyridine liés au carbone
WO2002034760A3 (fr) Composes et procedes
WO2008100620A3 (fr) Modulateurs de la cathepsine s à la tétrahydro-pyrazolo-pyridine aminopropyle bicycliques
WO2005067502A3 (fr) Modulateurs d'amide cyclopentyle d'alkylamino, arylamino et sulfonamido de l'activite des recepteurs de la chimiokine
WO2006004924A3 (fr) Composes imidazolo, compositions et leurs methodes d'utilisation
WO2008100622A3 (fr) Modulateurs de la cathepsine s à la tétrahydro-pyrazolo-pyridine substituée par un biaryle
WO2005058234A3 (fr) Methodes et compositions relatives a un antagoniste du ccr5, et inflammation induite par ifn-$g(g) et il-13
TW200745087A (en) CCR5 antagonists useful for treating HIV
WO2025006568A3 (fr) Inhibiteurs de mk2 et leurs procédés de fabrication et d'utilisation
WO2010041150A3 (fr) Peptides pharmaceutiques destinés au traitement d'affections inflammatoires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP